retatrutide phase 2 trial type 2 diabetes weight loss More data on dropped today at the ADA conference!! Reta is an investigational -not FDA approved yet- once-weekly medication that simultaneously activates the GIP, GLP-1, and glucagon receptors In the Retatrutide vs Eloralintide Obesity Therapies
Pay in 4 interest-free payments of $5.92 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 16 - Oct 21



























